The five Ig classes have distinct biological roles. The IgG subclasses also show marked differences in their ability to mediate a variety of effector functions. A detailed comparison of the properties of the human Ig classes and subclasses is not only of interest for relating the functions of antibodies to their structures but is also of great importance for the implementation of therapy based upon immunological intervention . Indeed, this second aspect has become particularly significant as the development of techniques for the production of chimeric antibodies (1-3) should ensure that immunological intervention is now likely to make use of mAbs that have human effector functions; several cell lines have already been established that secrete chimeric antibodies directed against human cancer cells (4-6).
The five Ig classes have distinct biological roles. The IgG subclasses also show marked differences in their ability to mediate a variety of effector functions. A detailed comparison of the properties of the human Ig classes and subclasses is not only of interest for relating the functions of antibodies to their structures but is also of great importance for the implementation of therapy based upon immunological intervention . Indeed, this second aspect has become particularly significant as the development of techniques for the production of chimeric antibodies (1) (2) (3) should ensure that immunological intervention is now likely to make use of mAbs that have human effector functions; several cell lines have already been established that secrete chimeric antibodies directed against human cancer cells (4-6).
Much of our knowledge of the properties of human Igs has been obtained from the study of myeloma proteins (reviewed in references 7-9). However, generally myeloma proteins do not bind identified antigens and, moreover, different myeloma proteins differ not only in their heavy chain class/subclass but also in their light chains and variable regions. As the initiation of antibody effector activity is usually a consequence of antigen binding and is indeed influenced by the quality of that binding, previous studies on myeloma proteins, although valuable, may not provide a sufficient picture of antibody effector function for therapeutic purposes . To carry out a detailed and controlled comparison of the effector functions of the different human C regions, we have established a panel of cell lines that secrete a matched set of human chimeric antibodies . These antibodies are directed against the hapten 4-hydroxy-3-nitrophenacetyl (NP).' This specificity for a known hapten has allowed us to compare the effector functions of the IgG subclasses not only when interacting with soluble antigen but also when interacting with cell-bound antigen. This has enabled us to determine the efficacy with which different subclasses lyse their This work was supported by grants from the Medical Research Council and Wellcome Biotechnology .
' Abbreviations used in this paper. ADCC, antibody-dependent cell-mediated cytotoxicity, NP, nitrophenacetyl ; NIP, 5-iodo-4-hydroxy-3-nitrophenyl .
PBS/Tween was added to each well and incubated at 37°C for 2 h. After extensive washing with PBS/Tween, 100 A,1 of a 1 :4,000 dilution in PBS/Tween of polyclonal sheep anti-mouse Ig antibody conjugated to horseradish peroxidase (BDS Biologicals Ltd ., Birmingham, United Kingdom) was added and incubated for a further 2 h at 37'C before repeated washing in PBS/Tween . Bound sheep antibody was revealed by addition of the substrate (2 .2 mM o-phenylene diamine) . The reaction was quenched after 15 min by the addition of 50 g.l 12 .5% H2 SO4 and the OD295 was measured using a Titertec Miniscan (Flow Laboratories, Irvine, Scotland) . Positive reactions were scored where the OD 295 was 0.5 OD units above control values .
Protein A Binding.
Purified antibodies (100 tig/ml in PBS) were coated onto the wells of microtiter plates (Cooke ; Dynatech Laboratories, Inc ., Alexandria, VA) before blocking with PBS/3% BSA. The wells were then incubated with ["'I]protein A (50,000 cpm per well; Amersham International, Amersham, United Kingdom), which had been diluted in citrate/phosphate buffer of the appropriate pH . The wells were washed at the same pH. Parallel incubations were also performed in which the plates were washed at the various pHs and the immobilized antibody developed with radio-iodinated monoclonal anti-A, antibody Ls136 (13) in PBS/1% BSA. This confirmed that the pH dependence observed in the protein A binding assays was indeed a result of the pH dependence of antibody/protein A interactions rather than artefact due to washing the chimeric antibody off the microtiter plate .
C1q Binding and Hemolysis Assays.
Human Clq that had been radioiodinated by the lactoperoxidase method was a gift from Dr. N . HughesJones and B. Gorick (MRC Centre, Cambridge, United Kingdom). Human erythrocytes were coupled with NIP-kephalin (gift of Dr . U. Weltzien, Max Planck Institute For Immunology, Freiburg, Federal Republic of Germany) as previously described (16) , and, if required, were labeled with sodium [5' Cr]chromate (Amersham International) as previously described (17) . For C 1 q binding assays, washed NIP-red cells (20 t1 at 109 cells/ml) in PBS/1% BSA were coated with saturating amounts of antibody (10 tL1 at 200 ug/ml) and then supplemented with ['25 1]Clq (10 Al at 10-60,ug/ml) . After rotation at 37°C for 1 h, samples were centrifuged in microfuge tubes through 150 Al of oil of density 1 .028 (made by mixing four parts din-butyl phthalate with one part dinonyl phthalate) . The cell pellets were separated by clipping off the bottom of the tube and the radioactivity in the bound and free fraction was determined . Controls were performed without added antibody; nonspecific binding was always <1 %.
For hemolytic complement assays, NIP-human red cells were labeled with 15'Cr ]-chromate, washed, and 50 ul of cells (109 /ml) were mixed in microtiter wells with 50 tul of appropriate dilutions of the chimeric antibodies . After 10 min at room temperature, 100 Al of diluted human complement was added to give a final concentration of 20% . After a 30-min incubation at 37°C, the cells and supernatant were separated by centrifugation (100 g, 2 min) . Samples incubated with no antibody were used to calculate the spontaneous "Cr release . The percentage specific "Cr release is calculated as: Percent release = 100 X [(Test release -spontaneous release)]/[(Total radioactivity) -(spontaneous release)] .
Antibody-dependent Cell-mediated Cytotoxicity. This was performed essentially as described (18) but with modifications. Cells (2 X 106) of the human T cell line HPB-ALL were labeled in 100,ul of medium with 50 tiCi of sodium [5 ' Cr]chromate for 30 min at 37°C, and 2 Al of NIP-kephalin (100 ug/ml) was then added and the incubation was continued for another 15 min. These target cells were then washed with Hepes-buffered Iscove's modified DME containing 1 % BSA . The effector cells were obtained from healthy donors by venipuncture and, after defibrination with glass beads, mononuclear cells were isolated by centrifugation on Ficoll-Hypaque (19) and cultured overnight in Iscove's MDM/5% FCS . Antibody-dependent cell-mediated cytotoxicity (ADCC) was measured by mixing labeled target cells (50 Al at 4 X 105/ml) with dilutions (100 Al) of the chimeric antibodies and then supplementing with the effector cells (50 11 at 1 .2 X 10'/ml) . The cells were pelleted (200 g, 10 min) and incubated at 37'C for 4 h . The radioactivity in the supernatant was then measured. Assays were performed in triplicate and controls pSV -VNP performed without effector cells (no lysis was then observed). The specific 5'Cr release was calculated as described above.
Results Cell Lines Expressing Human Chimeric Antibodies . The basic plasmid that was used for the construction of the chimeric heavy chain genes (pSV-V NP) is depicted in Fig. 1 . The plasmid contains the V gene of a mouse anti-NP antibody . Upstream of the V,, promoter is the mouse IgH enhancer element; downstream of VH is a unique Bam HI restriction site. Different human C,, genes were inserted either into this Bam HI site or into derivatives of pSV-VNP in which the Bam HI site was converted to a Hind III or Xba I site by insertion of linkers. The exact C,, fragments inserted are described in Fig. 1 . In the case of 73, two constructs were assembled with different y3 genes that originated from different sources, having been cloned from different individuals.
The gpt marker present in plasmid pSV-VNP allows stably transfected cells to be selected by virtue of their resistance to the drug mycophenolic acid. The plasmids were introduced into the mouse plasmacytoma J558L as described in Materials and Methods. This plasmacytoma secretes a X, light chain but expresses no heavy chain of its own. The VA of the endogenous light chain complements the VNP of the transfected heavy chain to yield an NP-specific antibody ; such antibodies display a slightly greater affinity for the iodinated derivative, NIP, than for NP itself.
Antibodies were purified to homogeneity from the culture medium of cloned transfectants ; yields were typically in the range 2 to 10 mg/liter although sometimes up to 30 mg/liter was achieved .
Analysis ofAntibodies on SDS/PAGE. To characterize the chimeric antibodies, purified samples were reduced and analyzed by SDS-PAGE . The mobilities of the heavy chains were much as predicted on the basis of their DNA sequences except for u, e, and a2. We have previously shown (3) that the chimeric e heavy chains become heavily glycosylated . We therefore resorted to biosynthetic labeling to compare the antibody normally secreted by the transfectants with that made in the presence of the glycosylation inhibitor tunicamycin. The results ( Fig. 2A) demonstrate the IgM, IgE, and IgA2 secreted by the J558L transfectants are indeed heavily glycosylated on their heavy chains . A much smaller amount of glycosylation is apparent on the 7 heavy chains . The sizes of the heavy chains of the unglycosylated antibodies are exactly as predicted from the DNA sequences (the y3 heavy chains standing out from the other 7 chains because of the long hinge) .
To examine whether the secreted antibodies were correctly assembled, unreduced samples were analyzed on 7% SDS-PAGE gels (Fig. 2B) . The IgGs and IgE exhibit mobilities consistent with their having the expected H2L2 structures whereas the IgM is clearly of very large molecular weight and, as expected for the pentameric form, scarcely enters the gel . IgA2 gives the most complex pattern and appears to contain H, HL, H2L2, and (H2 L2)2 forms; this may reflect the secretion of some noncovalently linked molecules.
Serological Characterization . For potential therapeutic applications, it is clearly important to establish whether chimeric human antibodies secreted by a mouse plasmacytoma are indeed homologous to human mAbs . While the analysis on SDS-PAGE indicated that the chimeric antibodies resembled their human counterparts as regards the molecular weights of both the native and the unglycosylated heavy chains, we decided to extend this characterization to include a wide
anon-19G3 range of serological markers. The chimeric antibodies were therefore typed using 37 different monoclonal anti-human antibodies (Fig. 3) . On the basis of this typing (Table I) , it will be seen that the two IgG3s are allotypically distinct . The y3 gene of the XEZZy3 clone (23) yields an IgG3 of the nG3m(g) isoallotype ; in other words, it is not of the G3m(g) allotype . Indeed, the DNA library from which the XEZZ-y3 clone was isolated was made from a Tunisian individual known to be homozygous for the G3m(b) allotype (23) . However, the y3 gene from the cosIgI clone (22) yields an IgG.G3m(g) antibody . The chimeric IgA2 types as nA2m (2), a result that is predicted from the sequence of the a2 gene used here which shows it to be of the A2m(1) allotype (27) . Thus, all the chimeric antibodies type exactly as expected and the chimeric antibodies are not therefore serologically distinguished in these assays from authentic human antibodies as regards the CH region determinants . Binding to Protein A. The chimeric antibodies were further tested in their binding of radio-iodinated Staphylococcal protein A over a pH range from 3 to 10 . The results (Fig. 4) indicate that the chimeric IgG1, IgG2, and IgG4 bind well to protein A and show a very similar pH dependence, binding occurring down to pH 4.5 . This similarity of pH dependence could be due to titration of one of the conserved residues in the antibody CH2/CH3 domain binding site for protein A (see review in reference 9) or could be due to titration of one of the protein A side chains themselves . * The y3 C region derives from clone coslgl (22) . $ The y3 C region derives from phage XEZZy3 (23) . assayed using various concentrations of radiolabeled C 1q and hapten-derivatized red cells that were coated with amounts of antibody that were shown to be saturating . The results (Fig. 5, left) show that Clq binding is detected with the IgM, IgGI, and both IgG3 antibodies but not with IgG2, IgG4, or IgE. The binding to IgM is weaker than to IgG 1 and IgG3 and, of these two IgG subclasses, the IgG3s bound more Clq than did the IgGI . Complement-mediated Hemolysis . Antibodies were tested over a wide concentration range for their ability to lyse hapten-coupled human red cells in the presence of human complement . The results (Fig. 5, right) show that IgG2, IgG4, and IgE did not mediate hemolysis, whereas IgM, IgG1, and both IgG3s were effective. Indeed, it is notable that the IgG 1 was considerably more effective in this hemolytic assay than the IgG3s. We have previously demonstrated (17) the efficacy of anti-NP antibodies in this hemolytic assay is critically dependent on their affinity for the hapten . However, this cannot explain the results obtained here . Binding-inhibition assays (not shown) indicate that the IgG 1 and IgG3 antibodies have indistinguishable affinities for NIP-caproate . Furthermore, the IgGI and IgG3 samples gave very similar titers in hemagglutination assays using hapten-derivatized red cells. Thus, although IgG3 is the best subclass as regards C 1 q binding it is considerably less potent than IgG 1 in hemolytic assays . Interestingly, a similar but less marked reversal of hemolytic efficiency as compared with Clq binding is observed with the two IgG3 allotypes. Whereas the IgG.G3m(g) binds Clq slightly better, the IgG.G3m(b) is somewhat more effective in hemolysis. Antibody-dependent Cell-mediated Cytotoxicity . The efficacy of the antibodies in mediating ADCC was tested using a hapten-derivatized human T cell line (HPB-ALL) as target and mononuclear cells from human volunteers as effector cells. It was found (Fig . 6 ) that only IgGI and IgG3 were effective in mediating ADCC with the IgG 1 showing greater potency than either of the IgG3s.
Discussion
The cell lines established during the course of this work provide a source of chimeric antibodies that can be easily purified to homogeneity in a one-step purification on hapten sorbents. To confirm that these chimeric human antibodies made in mouse plasmacytoma cells exhibit the features expected of antibodies possessing human C regions, we have characterized the antibodies as regards their serological properties, the mobilities in SDS-PAGE of both the native and the unglycosylated forms as well as their binding to protein A. In all these respects, the chimeric antibodies behave exactly as expected from their authentic human counterparts .
The known antigen specificity of these chimeric antibodies has allowed us to assay their efficacy in complement-mediated lysis and in ADCC . This has given rise to some novel and unexpected findings . The hierarchy of the binding of the aggregated chimeric IgG subclasses to human C lq described here agrees well with the previous results on the hierarchy in C 1 q binding of monomer IgG myeloma subclasses (28) ; however, aggregated IgG will bind with a higher avidity than monomeric IgG. Nevertheless, when we measured the efficacy of the antibodies in complement-mediated hemolysis, a very different result was obtained . It is evident that the IgGI is very much more effective than the IgG3 in this assay. At present it is not clear why there is this lack of correlation between Clq binding and hemolytic efficacy ; it will clearly be of interest to compare the IgG1 and IgG3 chimeric antibodies in intermediate stages of the pathway such as C1 activation and C4 and C3 binding. It will also be of interest to determine how the comparative hemolytic efficacy of IgGI and IgG3 depends upon the density and nature of the antigen on the target cell.
The results presented here also indicate that the IgGI and IgG3 are the only antibodies that are really effective in ADCC. The greater effectiveness of IgGI as compared with IgG3 is a novel and interesting finding. The relative inactivity of the IgG2 and IgG4 antibodies was, however, predictable. Although the exact nature of the effector cell responsible for mediating ADCC has not been unambiguously identified, the Fc receptors found on the possible effector cell types (lymphocytes and monocytes) bind IgGI and IgG3 much better than IgG2 and IgG4 (reviewed in reference 9).
Finally, it is worth noting that the results obtained in this work suggest that for many therapeutic purposes an IgGI antibody might be greatly preferred to the other IgG subclasses as it appears to be considerably more effective in mediating both complement-dependent lysis and ADCC . Summary Cell lines have been established that secrete a matched set of human chimeric IgM, IgG l, IgG2, IgG3, IgG4, IgE, and IgA2 antibodies that are directed against the hapten 4-hydroxy-3-nitrophenacetyl . These chimeric antibodies secreted from mouse plasmacytoma cells behave exactly like their authentic human counterparts in SDS-PAGE analysis, binding to protein A and in a wide range of serological assays. The antibodies have been compared in their ability to bind human Clq as well as in their efficacy in mediating lysis of human erythrocytes in the presence of human complement. A major conclusion to emerge is that whereas IgG3 bound C 1 q better than did IgG l , the chimeric 1gG1 was much more effective than all the other IgG subclasses in complement-dependent hemolysis. The IgG1 antibody was also the most effective in mediating antibodydependent cell-mediated cytotoxicity using both human effector and human target cells. These results suggest that IgGI might be the favoured IgG subclass for therapeutic applications .
